Table 2.

CV clinical outcomes in the PSM cohort

Outcomes	SGLT2i	SGLT2i-free	Unadjusted Model			Model 1			Model 2
			HR	95% CI	P Value	Adjusted HR	95% CI	P Value	Adjusted HR	95% CI	P Value
MACE	41(18.1)	69(30.5)	0.545	0.370–0.803	0.002	0.657	0.483–0.893	0.007	0.659	0.487–0.892	0.007
All-cause Death	2(0.9)	5(2.2)	0.783	0.514–1.191	0.253	0.763	0.561–1.040	0.087	0.763	0.560–1.039	0.086
CV death	1(0.4)	4(1.8)	0.798	0.640–0.995	0.045	0.878	0.779–0.990	0.033	0.880	0.783–0.990	0.033
Heart failure readmission	7(3.1)	18(8.0)	0.462	0.236–0.902	0.024	0.543	0.330–0.894	0.016	0.545	0.332–0.893	0.016
Recurrent MI	10(4.4)	14(6.2)	0.801	0.477–1.345	0.401	0.638	0.099–4.093	0.635	0.637	0.099–4.096	0.635
Stroke	12(5.3)	17(7.5)	0.833	0.573–1.210	0.337	0.748	0.381–1.471	0.400	0.748	0.380–1.471	0.400
Revascularization	10(4.4)	15(6.6)	0.751	0.434–1.297	0.304	0.914	0.417–2.004	0.822	0.913	0.414–2.014	0.822

CI, confidence level; CV, cardiovascular; MACE, major adverse cardiovascular events; MI, myocardial infarction; HR, hazard ratio; SGLT2i, Sodium-glucose cotransporter 2 inhibitor

Model 1: Adjusted for age, gender, diabetes duration, hypertension history, hyperlipidemia, chronic heart failure, percutaneous coronary intervention (PCI), acute coronary syndrome (ACS) type, and extent of ACS disease

Model 2: Adjusted for covariates in model 1 and GLP-1RA and eGFR